Royalty Pharma plc

Informe acción NasdaqGS:RPRX

Capitalización de mercado: US$12.4b

Salud financiera de hoja de balance de Royalty Pharma

Salud financiera controles de criterios 4/6

Royalty Pharma tiene un patrimonio de accionistas total de $10.1B y una deuda total de $6.1B, lo que sitúa su ratio deuda-patrimonio en 60.8%. Sus activos y pasivos totales son $16.4B y $6.3B respectivamente. El BAIT de Royalty Pharma es de $1.5B, por lo que su ratio de cobertura de intereses es de 13. Tiene efectivo e inversiones a corto plazo que ascienden a $495.3M.

Información clave

62.2%

Ratio deuda-patrimonio

US$6.14b

Deuda

Ratio de cobertura de intereses7.7x
EfectivoUS$872.00m
PatrimonioUS$9.86b
Total pasivoUS$6.27b
Activos totalesUS$16.13b

Actualizaciones recientes sobre salud financiera

Recent updates

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25
Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22
Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26
Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Royalty Pharma declares $0.19 dividend

Jul 15

Royalty Pharma: Unique Diversification, Bear Market Performer

May 26

The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Apr 25
The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($1.3B) de RPRX superan a sus pasivos a corto plazo ($161.4M).

Pasivo a largo plazo: Los activos a corto plazo ($1.3B) de RPRX no cubren sus pasivos a largo plazo ($6.1B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de RPRX (55.9%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de RPRX ha pasado de 143.2% a 60.8% en los últimos 5 años.

Cobertura de la deuda: La deuda de RPRX está bien cubierta por el flujo de caja operativo (48.7%).

Cobertura de intereses: Los pagos de intereses de la deuda de RPRX están bien cubiertos por el BAIT (13x cobertura).


Hoja de balance


Descubre empresas con salud financiera